Aurora Cannabis Logo
CA05156X8843
A2P4EC
21P1.F

Aurora Cannabis

Forecast

Buy
  0
Hold
  5
Sell
  2

Discussions in the community

  • Translated from German

    Position remains displayed despite deletion confirmation

    PN Parqet Nutzer V in Schnack

    0 4
  • Probleme mit meinem Depot...

    MaxPower MaxPower V in Schnack

    0 23
  • Translated from German

    Chart Outlier

    W Wolfgang II in Schnack

    0 12

  • Aurora Cannabis records 11% revenue growth in 2026 and debt-free balance sheet, stock falls

    Aurora Cannabis reported net revenue of CAD 321 million for fiscal 2026 (+11%) and adjusted EBITDA of CAD 54 million (+32%). Growth was driven by international expansion and a focus on higher-margin medical cannabis; international markets accounted for 55% of revenue. The company is debt-free and holds CAD 165 million in cash, and it forecasts Q1 FY2027 EPS of -0.08 USD and revenue of USD 54.94 million. The stock fell 2.96% after the results were released. » More on de.investing.com


  • Aurora Cannabis expects decline in quarterly revenue and moderate loss per share

    Aurora Cannabis will release results for the quarter ended 31/03/2026 on 11/06/2026. Five analysts expect an average loss of -0.058 CAD per share (prior year: -0.350 CAD) and six analysts forecast revenue of 75.7 million CAD, about 16.4% below last year’s 90.5 million CAD. For the past fiscal year, five analysts estimate an average loss of -1.197 CAD per share and six analysts see annual revenue at 358.4 million CAD (prior year: 343.3 million CAD). » More on finanzen.net


  • Aurora Cannabis expands medical portfolio in Canada, Europe and Australia

    Aurora Cannabis will launch new medical cannabis products by June in Canada, Germany, Poland and Australia, including dried flower, pre-rolls and lozenges. In Germany the company will offer San Raf Pink OG Kush (25–27% THC) and Daily Special Lemon Sorbet (21% THC); Poland and Australia will also receive high‑potency strains and multi‑stage lozenge formulations. The products are manufactured in GMP‑certified facilities in Canada and Germany and are part of the company’s international “Medical‑First” strategy. Aurora has a market capitalization of about USD 207.74 million and recorded a 25% share price decline in the past year, while InvestingPro currently rates the stock as undervalued. » More on de.investing.com


  • Aurora Cannabis buys Safari Flower for $26.5 million to bolster EU‑GMP capacity

    Aurora Cannabis is acquiring the Safari Flower Company for $26.5 million, to be paid with $15 million in cash, 2,417,180 common shares and a conditional $2 million earn‑out. Safari operates a 59,000‑square‑foot EU‑GMP‑certified indoor facility in Ontario, whose capacity Aurora plans to use for exports to Germany, Australia, Poland and the UK. The acquisition represents about 13% of Aurora’s market capitalization and is expected to contribute positively to adjusted EBITDA from fiscal 2027, with further effects anticipated from 2028. » More on de.investing.com


  • Aurora Cannabis: revenue rises, but net loss in third quarter

    Aurora Cannabis reported a net loss from continuing operations of CAD 1.7 million in the third quarter of fiscal 2026, compared with a net profit of CAD 28.1 million a year earlier. Revenue rose to CAD 94.191 million (prior year CAD 88.2 million) and exceeded analysts’ expectations of CAD 92.4 million. Adjusted net income remained virtually unchanged at CAD 7.2 million; the global medical cannabis business posted record quarterly net revenue of USD 76.2 million, adjusted EBITDA of USD 18.5 million and free cash flow of USD 15.5 million. The stock reacted with declines, dropping as much as about 6.2% to USD 3.81. » More on finanzen.net

Financials

In the last year, Aurora Cannabis had revenue of €270.28M and net profit of -€69.33M

(EUR) 2024
YoY
Revenue 270.28M 15.86%
Gross profit 131.46M 304.26%
Net profit -69.33M 73.87%
EBITDA -12.34M 94.14%

Fundamentals

Metric Value
Market capitalization
€19.64M
Number of shares
54.54M
52-week high/low
€1.08 - €0.35
Dividends No
Beta
2.86
P/E ratio
-4.44
PEG ratio
0.03
P/B ratio
0.75
P/S ratio
1.37

Company profile

Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Name
Aurora Cannabis
CEO
Miguel Martin
Headquarters Edmonton, ab
Canada
Website
Sector
Health Care
Industry
Pharmaceuticals
IPO
07/15/2014
Employees 1,130

Ticker symbols

Exchange Symbol
XETRA
21P1.F
🍪

Parqet  uses cookies. Learn more